SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Diabetes and Vascular Disease Research

Volumn 12, Issue 2, 2015, Pages 90-100

  Inzucchi, Silvio E ^a   Zinman, Bernard ^b   Wanner, Christoph ^c   Ferrari, Roberto ^d,e   Fitchett, David ^f   Hantel, Stefan ^g   Espadero, Rosa Maria ^h   Woerle, Hans Jürgen ^g   Broedl, Uli C ^g   Johansen, Odd Erik ⁱ  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e MARIA CECILIA HOSPITAL   (Italy)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h Health Economics and Outcomes Research   (Spain)

ⁱ Boehringer Ingelheim KS   (Norway)

Author keywords

cardiovascular complications; macrovascular; review; sodium glucose cotransporter 2 inhibitors; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; ARTERIAL STIFFNESS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETIC MICROANGIOPATHY; FAT MASS; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEINURIA; REVIEW; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY PROXIMAL TUBULE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; URINARY EXCRETION;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; RENAL ELIMINATION; RENAL REABSORPTION; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84923448295     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114559852     Document Type: Review

References (86)

1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006 ; 332: 73-78
2. Sloan FA, Bethel MA, Ruiz D, et al. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med. 2008 ; 168: 192-199
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 ; 35: 1364-1379
4. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013 ; 34: 3035-3087
5. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009 ; 32: 187-192
6. Johansen OE. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Invest. 2007 ; 67: 786-800
7. Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013 ; 36: 2271-2279
8. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 ; 154: 602-613
9. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 ; 369: 1317-1326
10. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 ; 369: 1327-1335
11. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011 ; 55: 10-16
12. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991 ; 121: 1244-1263
13. Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA. 2013 ; 310: 2609-2610
14. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009 ; 53: 875-883
15. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994 ; 93: 397-404
16. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002677/human-med-001764.jsp&mid=WC0b01ac058001d124 (accessed 29 August 2014)
17. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human-med-001546.jsp&mid=WC0b01ac058001d124 (accessed 29 August 2014)
18. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002649/human-med-001707.jsp&mid=WC0b01ac058001d124 (accessed 29 August 2014)
19. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204629s000lbl.pdf (accessed 20 September 2014)
20. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204042s002lbl.pdf (accessed 20 September 2014)
21. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202293s003lbl.pdf (accessed 20 September 2014)
22. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 ; 85: 513-519
23. Obermeier MT, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dis. 2010 ; 38: 405-414
24. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013 ; 4: 331-345
25. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011 ; 13: 669-672
26. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 ; 159: 262-274
27. Mellbin LG, Rydén L, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013 ; 34: 3137-3144
28. Patrick AW, Hepburn DA, Swainson CP, et al. Changes in renal function during acute insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabet Med. 1992 ; 9: 150-155
29. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 ; 124: 499-508
30. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care?. Diabetes Care. 2011 ; 34: S120 - S127
31. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 ; 124: 509-514
32. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 1996 ; 93: 1809-1817
33. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetes Care. 2014 ;:
34. Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 ; 15: 853-862
35. Mancia G, Cannon CP, Tikkanen I, et al. BP reduction with the sodium glucose co-transporter 2 inhibitor empagliflozin in type 2 diabetes is similar in treatment naïve as in those on one or2 antihypertensive agents - further insights from a Dedicated 24h ABPM Study. Circulation. 2014 ; 129: A2343
36. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014 ; 13: 28
37. Zimlichman R. Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep. 2014 ; 16: 479
38. MacEwan A, McKay GA, Fisher. M. Drugs for diabetes: part 8 SGLT2 inhibitors. Br J Cardiol. 2012 ; 19: 26-29
39. Ferrannini G, Hach T, Crowe S, et al. Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition. Diabetologia. 2014 ;:
40. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006 ; 444: 881-887
41. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013 ; 34: 1-11
42. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013 ; 382: 941-950
43. Bolinder J, Ljunggren Ø, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diab Obes Metab. 2014 ; 16: 159-169
44. Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014 ; 2: 691-700
45. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index. A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010 ; 33: 920-922
46. Luo W, Guo Z, Wu M, et al. Index of central obesity as a parameter to replace waist circumference for the definition of metabolic syndrome in predicting cardiovascular disease. J Cardiovasc Med. 2014 ; 15: 738-744
47. Neeland IJ, McGuire DK, Chilton B, et al. The Sodium Glucose Co-transporter 2 Inhibitor (SGLT2i) Empagliflozin reduces weight and markers of visceral adiposity (VA) in type 2 diabetes (T2D) in short- and intermediate term. Circulation. 2014 ; 129: A2340
48. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus on inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 ; 97: 1020-1031
49. Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating 'sick fat' through improving fat function with antidiabetes therapies. Am J Cardiol. 2012 ; 110: 4B - 12B
50. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diab Obes Metab. 2013 ; 15: 463-473
51. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014 ; 85: 962-971
52. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised double-blind placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 ; 2: 369-384
53. Cherney D, von Eynatten M, Lund S, et al. Sodium glucose cotransporter 2 (SGLT2) inhibition with empagliflozin (EMPA) reduces microalbuminuria in patients with type 2 diabetes (T2D). Diabetes. 2014 ; 63 :
54. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971 ; 28: 101-109
55. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005 ; 54: 3427-3434
56. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 ; 129: 587-597
57. ŠkrtiM, Yang GK, Perkins BA, et al. Characterization of glomerular hemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014 ; 57: 2599-2602
58. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int. 2014 ; 86: 693-700
59. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009 ; 53: 796-803
60. Ndrepepa G, Braun S, King L, et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism. 2012 ; 61: 1780-1786
61. Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014 ; 16: 15-24
62. Zand S, Shafiee A, Boroumand M, et al. Serum uric acid is not an independent risk factor for premature coronary artery disease. Cardiorenal Med. 2013 ; 4: 246-253
63. Hach T, Gerich J, Salsali A, et al. Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trials. Diabetes. 2013 ; 62 :
64. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet. 2010 ; 375: 2223-2233
65. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012 ; 35: 1232-1238
66. Cheesman C. Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens. 2009 ; 18: 428-432
67. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014 ; 16: 457-466
68. Hardy E, Ptanszynska A, de Bruin TWA, et al. Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy. Diabetologia. 2013 ;: 61
69. Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014 ; 14: 37
70. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycaemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metabolism. 2013 ; 17: 695-708
71. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J of Pharmacol. 2013 ; 715: 246-255
72. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?. PLoS ONE. 2013 ; 8: e54442
73. Osorio H, Coronel I, Arellano A, et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev. 2012 ; 2012: 542042
74. Younis FM, Hollander K, Mayoux EW, et al. Effect of prophylactic treatment with empagliflozin on cardiac function and diabetes in CRDH rats. Diabetes. 2014 ; 63 :
75. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10 mg, http://www.fda.gov/DOWNLOADS/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ENDOCRINOLOGICANDMETA-BOLICDRUGSADVISORYCOMMITTEE/UCM262994.PDF (accessed 29 August 2014).
76. FDA briefing material, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (accessed 20 September 2014).
77. Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment vs. standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014 ; 16: 628-635
78. Food and Drug Administration (Center for Drug Evaluation and Research). Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf (accessed 20 September 2014).
79. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf (accessed 17 October 2014).
80. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014 ; 13: 102
81. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - a randomized placebo-controlled trial. Am Heart J. 2013 ; 166: 217-223
82. CANVAS (clinicaltrials.gov identifier: NCT01032629).
83. DECLARE-TIMI58 (clinicaltrials.gov identifier: NCT01730534).
84. Clintrials.gov. CANVAS-R, http://www.clinicaltrials.gov/ct2/show/NCT01989754?term=canvas-r&rank=1
85. Clin.trials.gov. CREDENCE, http://www.clinicaltrials.gov/ct2/show/NCT02065791?term=CREDENCE&rank=2
86. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs - insights from the rosiglitazone experience. N Engl J Med. 2013 ; 369: 1285-1287